AB Science S.A. (EPA:AB)
1.186
+0.006 (0.51%)
At close: Nov 28, 2025
AB Science Revenue
AB Science had revenue of 515.00K EUR in the half year ending June 30, 2025, with 14.96% growth. This brings the company's revenue in the last twelve months to 1.03M, down -5.08% year-over-year. In the year 2024, AB Science had annual revenue of 1.07M with 10.52% growth.
Revenue (ttm)
1.03M
Revenue Growth
-5.08%
P/S Ratio
84.24
Revenue / Employee
28.53K
Employees
39
Market Cap
86.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.07M | 102.00K | 10.52% |
| Dec 31, 2023 | 970.00K | 12.00K | 1.25% |
| Dec 31, 2022 | 958.00K | -649.00K | -40.39% |
| Dec 31, 2021 | 1.61M | 24.00K | 1.52% |
| Dec 31, 2020 | 1.58M | 12.00K | 0.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
AB Science News
- 12 days ago - Bitcoin Rebounds To $93,000 As Ethereum, XRP, Dogecoin Rise 3% - Benzinga
- 18 days ago - Bitcoin Slips Below $102,000 As Ethereum, XRP, Dogecoin Drop Over 2% - Benzinga
- 4 weeks ago - Q3 2025 Fingerprint Cards AB Earnings Call Transcript - GuruFocus
- 5 weeks ago - The AI Boom: Bubble Or Bonanza? - Seeking Alpha
- 6 weeks ago - AB Science S.A. (ABSCF) Discusses Clinical Update on AB8939 Combined With Venetoclax for Refractory and Relapsed AML With Poor Genetics Transcript - Seeking Alpha
- 3 months ago - Market concentration is scary and it's all around AI, says AB's Jim Tierney - CNBC
- 4 months ago - AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS - Benzinga
- 4 months ago - 'Top priority is to grow portfolio of companies,' Investor AB CEO says - CNBC